Glioblastoma is a aggressive brain cancer known for its quick growth and resistance to standard treatments. Investigations are constantly underway to identify new treatment strategies, and recently, a new biomarker named LCA168 has emerged as a potential avenue for GBM treatment. LCA168 is a protein that is overexpressed in GBM cells compared to n